Shopping Cart
Remove All
Your shopping cart is currently empty
Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | - | In Stock | |
| 5 mg | $753 | - | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,780 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
| Description | Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection. |
| In vitro | Romlusevimab showed a high binding affinity for RBD with an equilibrium dissociation constant (KD) of 0.56 nM. The mixture of Amubarvimab and Romlusevimab blocks the binding of human ACE2 receptor to RBD, IC50 = 16.36 nM. The neutralizing activity of Romlusevimab against Neut99 was 2.50 μg/mL. [1] |
| In vivo | Amubarvimab and Romlusevimab at a 1:1 mixture of 10 mg/kg or 50 mg/kg intritoneally injected into hamsters showed potent activity against SARS-CoV-2. [1] |
| Synonyms | BRII-198, BRII198 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Spike RBD |
| Molecular Weight | 143.4 kDa |
| Cas No. | 2509447-08-7 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 lambda C2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.